Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM, Que YA, Vouillamoz J, Glauser MP, Moreillon P. Entenza JM, et al. Among authors: que ya. Antimicrob Agents Chemother. 2001 Nov;45(11):3076-83. doi: 10.1128/AAC.45.11.3076-3083.2001. Antimicrob Agents Chemother. 2001. PMID: 11600359 Free PMC article.
Reply to Eisen and McBryde.
Veloso TR, Que YA, Moreillon P, Entenza JM. Veloso TR, et al. Among authors: que ya. J Infect Dis. 2015 Aug 15;212(4):674-5. doi: 10.1093/infdis/jiv133. Epub 2015 Mar 9. J Infect Dis. 2015. PMID: 25754979 No abstract available.
Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens.
Shlezinger M, Khalifa L, Houri-Haddad Y, Coppenhagen-Glazer S, Resch G, Que YA, Beyth S, Dorfman E, Hazan R, Beyth N. Shlezinger M, et al. Among authors: que ya. Curr Top Med Chem. 2017;17(10):1199-1211. doi: 10.2174/1568026616666160930145649. Curr Top Med Chem. 2017. PMID: 27770768 Review.
Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, Schaal JV, Soler C, Fevre C, Arnaud I, Bretaudeau L, Gabard J. Jault P, et al. Among authors: que ya. Lancet Infect Dis. 2019 Jan;19(1):35-45. doi: 10.1016/S1473-3099(18)30482-1. Epub 2018 Oct 3. Lancet Infect Dis. 2019. PMID: 30292481 Clinical Trial.
115 results